February 2011
Pharmaceutical Representative;Feb2011, Vol. 41 Issue 2, p10
The article offers world news briefs related to various clinical studies in medicines. It states the preliminary result of a study conducted by Forest Laboratories Inc. and Pierre Fabre Medicament for the treatment of major depressive disorder (MDD). It relays the clinical trial initiated by Regeneron Pharmaceuticals Inc. and Bayer HealthCare LLC in collaboration with Singapore Eye Research Institute (SERI). It reports the new data from Pacira Pharmaceuticals from its study on placebo treatment.


Related Articles

  • Forest Laboratories and Pierre Fabre Medicament Announce 3rd Positive Phase III Study for Levomilnacipran in Patients with Major Depressive Disorder.  // Biomedical Market Newsletter;4/28/2012, Vol. 21, p1 

    The article provides information on the results from Phase III clinical trial of levomilnacipran, an investigational agent for the treatment of adults with major depressive disorder (MDD), conducted by Forest Laboratories Inc. and the company Pierre Fabre Medicament. The study showed that...

  • Regeneron Extends Vision for VEGF Drug to DME.  // Bioworld Week;4/18/2011, Vol. 19 Issue 16, p2 

    The article looks at the efforts of Regeneron Pharmaceuticals Inc. and Bayer Healthcare in introducing a new drug VEGF Trap-Eye afilbercept opthalmic solution used to manage age-related macular degeneration particularly diabetic macular edema (DME) among adults younger than 50.

  • Regeneron, Bayer eye Landmark at Eastview deals. Philippidis, Alex // Westchester County Business Journal;10/16/2006, Vol. 45 Issue 42, pS10 

    The article reports that the Regeneron Pharmaceuticals Inc. and Bayer HealthCare LLC are pursuing lease deals at The Landmark office-laboratory campus in New York. The facility is working out leases with Regeneron for more than half the space of a new three-building and with Bayer for Diabetes...

  • Positive Results of Two Phase Ill Studies with VEGF Trap-Eye.  // Review of Ophthalmology;Dec2010, Vol. 17 Issue 12, p4 

    The article discusses the results of Phase III studies on patients with the neovascular form of age-related macular degeneration (AMD) by Regeneron Pharmaceuticals Inc. and Bayer Healthcare LLC in the U.S. It was found that all regimens of VEGF Trap-Eye met the primary endpoint compared to...

  • Regeneron Stock Up 19.7% After Positive VEGF Trap-Eye Report. Wall, Tom // BioWorld Today;11/23/2010, Vol. 21 Issue 227, p1 

    The article reports that stock price in Regeneron Pharmaceuticals Inc. increased by 4.86 U.S. dollars to 29.53 U.S. dollars following the release of data from the company and partner Bayer HealthCare on two parallel Phase III studies of VEGF Trap-Eye. Primary endpoints were met in the trials...

  • Regeneron Extends Vision for VEGF Drug to DME. Shaffer, Catherine // BioWorld Today;4/11/2011, Vol. 22 Issue 69, p1 

    The article reports that Regeneron Pharmaceuticals Inc. and Bayer HealthCare have begun Phase III trials for vascular endothelial growth factor (VEGF) Trap-Eye, afilbercept ophthalmic solution, in diabetic macular edema (DME). It discusses how DME has caused vision loss in adults younger than...

  • Two studies test efficacy of VEGF Trap-Eye treatment.  // Ocular Surgery News Europe;Jan2011, Vol. 22 Issue 1, p1 

    The article discusses research by Bayer and Regeneron that evaluate the efficiency of vascular endothelial growth factor (VEGF) Trap-Eye in fighting eye conditions like macular edema secondary and central retinal vein occlusion. The GALILEO and COPERNICO studies detect the success of the...

  • Pharmaceutical firm reports losses.  // Hudson Valley Business Journal;3/6/2006, Vol. 17 Issue 5, p8 

    The article reports that Regeneron Pharmaceuticals Inc. has reported a net loss for the fourth quarter of 2005.

  • BD, Aethon To Focus on Medication Management.  // Chain Drug Review;1/19/2015, Vol. 38 Issue 2, p25 

    The article offers pharmaceutical industry news briefs including the collaboration between Aethon Inc. and BD, the World Pharmacist Day celebration to be held on September 25, 2015, and the "Cholesterol Counts" program launched by Regeneron Pharmaceuticals Inc. and Sanofi U.S.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics